{"analyses":[{"ciLowerLimit":"0.58","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.83","estimateComment":"Hazard ratios are estimated using a Pike estimator.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.70"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.1","upperLimit":"33.8","value":"26.0"},{"groupId":"OG001","lowerLimit":"15.6","upperLimit":"20.7","value":"17.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"352"},{"groupId":"OG001","value":"352"}],"units":"Participants"}],"description":"Overall Survival (OS) was defined as the interval of time between the date of randomization and the date of death due to any cause. For patients who did not die, OS was censored at the date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dabrafenib 150 milligrams (mg) orally twice daily (BID) and Trametinib 2 mg orally once daily until disease progression, death, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Dabrafenib Plus Trametinib"},{"description":"Vemurafenib 960 mg orally BID until disease progression, death, unacceptable toxicity, or withdrawal of consent.","id":"OG001","title":"Vemurafenib"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat (ITT) Population.","reportingStatus":"POSTED","timeFrame":"From the date of randomization until date of death due to any cause (up to approximately 6 years)","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Months"}